Average Co-Inventor Count = 7.74
ph-index = 11
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (48 from 3,684 patents)
2. Universitéde Montreal (8 from 183 patents)
3. Viiv Healthcare UK (no.5) Limited (2 from 42 patents)
4. Bristol-myers Company (1 from 637 patents)
5. Fabre-kramer Pharmaceuticals, Inc. (1 from 1 patent)
6. Viiv Healthcare UK Limited (9 patents)
7. Bristol-myers Squibb Holdings Ireland (0 patent)
52 patents:
1. 12084452 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
2. 12037324 - Biarylmethyl heterocycles
3. 11407733 - Biarylmethyl heterocycles
4. 10822343 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
5. 10428077 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
6. 10238638 - Benzothiazole and benzothiophene compounds
7. 10047103 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
8. 9862730 - Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
9. 9758487 - Hepatitis C virus inhibitors
10. 9688695 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
11. 9655888 - Tricyclic alkene derivatives as HIV attachment inhibitors
12. 9505752 - Piperidine amide derivatives as HIV attachment inhibitors
13. 9227961 - Hepatitis C virus inhibitors
14. 9018390 - Hepatitis C virus inhibitors
15. 8846023 - Hepatitis C virus inhibitors